Recent advances in immunotherapy of acute leukemia via chimeric antigen receptor-engineered T cells

Abstract

Adoptive transfer of T cells transduced with a chimeric antigen receptor to treat relapsed or refractory acute leukemia: efficacy and feasibility of immunotherapy approaches SCIENCE CHINA Life Sciences 59, 673 (2016); Treatment of solid tumors with chimeric antigen receptor-engineered T cells: current status and future prospects SCIENCE CHINA Life Sciences 59, 360 (2016);

Advances in antitumor chemotherapy effects on immune function

“…化疗后或 化疗期间加入免疫疗法为一种可行的方式 [10] . 通过化 疗(尤其低剂量)增强肿瘤免疫原性、激活效应细胞, 再 使用免疫治疗, 如免疫检查点抑制剂 [115] 、刺激分 子 [116,117] 、肿瘤疫苗 [118,119] 、固有免疫成分 [120,121] 、嵌 合抗原受体T细胞(chimeric antigen receptor T-cell, CAR- T) [122,123] 等, 可进一步活化、维持免疫细胞效能, 攻击肿 瘤靶点. 另外, 先通过免疫治疗强化免疫功能, 随后再 化疗也被证实能发挥更佳的抗肿瘤效果, 而且对免疫 系统杀伤毒性更小, 化疗剂量也可适度降低 [72,124,125] .…”